FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

CIPLA Share Price Discussion

Cipla Ltd.
Sector: Pharmaceuticals and health care
... Read more
CIPLA Share Price *
449.15 -6.3 (-1.38%)
* (quote may be delayed)

Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?


You can also check CIPLA share price target recommended by brokerages.

CIPLA Discussion Forum


CIPLA - chart - 473536
# CIPLA OVERVIEW
Cipla target 435 and find resistance at 463
Like
reply
Reply
share
Share

CIPLA - chart - 472449
BUY CIPLA 456.9 TARGET 462-467-472 STOPLOSS 455.35
find view usefull - kindly post your comment - click like button - follow and enjoy benefits
all my views on intraday basis - Views given with clear entry target and very small stoploss
1
reply
Reply
share
Share

Cipla
facing resistance
491
And support placed 389
Like
reply
Reply
share
Share
SAGAANI in CIPLA
BUY CIPLA 462.25 TARGET 467-472.3-478 STOPLOSS...

CIPLA - chart - 470326
1 ST TARGET DONE - HAPPY TRADING
Like
reply
Reply
share
Share

CIPLA - chart - 470322
1 TARGET DONE
BUY CIPLA 462.25 TARGET 467-472.3-478 STOPLOSS 460.85
1 st target done - happy trading
find view usefull - kindly post your comment - click like button - follow and enjoy benefits
all my views on intraday basis - Views given with clear entry target and very small s...
Read more...
Like
reply
Reply
share
Share

CIPLA - chart - 470056
BUY CIPLA 462.25 TARGET 467-472.3-478 STOPLOSS 460.85
find view usefull - kindly post your comment - click like button - follow and enjoy benefits
all my views on intraday basis - Views given with clear entry target and very small stoploss
Like
reply
Reply
share
Share
Shardia in CIPLA
SL on cost due to some support

Booked 465
Like
reply
Reply
share
Share
Shardia in CIPLA
Sell cipla 466-67 sl 471

463.85
Like
reply
Reply
share
Share
Shardia in CIPLA
Sell cipla 466-67 sl 471

SL on cost due to some support
Like
reply
Reply
share
Share

Sell cipla 466-67 sl 471
Like
reply
Reply
share
Share

Buy cipla 471 sl 465 tgt 476, 481
Like
reply
Reply
share
Share

BUY CIPLA 468.5 AND in dips till 452.5 SL 442.5 TARGET 490/520 DELIVERY
#TradeAdda
Like
reply
Reply (1)
share
Share
Latest replies

Sir are zeel and gail good bet to buy at current rates
Exclusive | Cipla leads race for Wockhardt's business divisions
Wockhardt, wants to reduce its debt burden and is seeking a valuation between Rs 2,400 crore and Rs 2,700 crore
Moneycontrol
Like
reply
Reply
share
Share
SHREE NAGENDRA SHARES in CIPLA
BUY CIPLA ABOVE ⬆️ 473 TGS 476 » 479 » 482 ...

CARRY FORWARD : CIPLA
1
reply
Reply
share
Share

BUY CIPLA ABOVE ⬆️ 473 TGS 476 » 479 » 482 UPTO 490 SL 465
Like
reply
Reply
share
Share

Cipla's wholly-owned subsidiary Cipla (EU) Ltd., holding a 60% stake in Cipla Pharma Lanka, has signed an agreement with CitiHealth Imports to acquire the remaining 40% stake in Cipla Pharma Lanka. Post the acquisition, Cipla Pharma Lanka will become a wholly-owned subsidiary.
1
reply
Reply
share
Share

CIPLA - 455697

Like
reply
Reply (2)
share
Share
Latest replies

Tomorrow uptrend or down trend any updates
Invictus @invictotrader
Nov 27 1:53 AM

I would suggest no trade zone between 472-79, this range is very strong support as per previous data, if sustained at this level then only we can see more upsides..

CIPLA - 454430
BUY CIPLA 484 TARGET 489-494.5-500 STOPLOSS 482.35
Image
1 st target done
happy trading
Like
reply
Reply
share
Share

STBT: EXIT SHORT FROM CIPLA AS SL HIT AT 485, LOSS RS 5500.
Like
reply
Reply
share
Share

Cipla
-WW in Cipla (Positional - 15 min Closing Bias SL)
Sell in 502 to 505 with SL of 510.1 for 494, 486
CMP 478 @ 11/23
Like
reply
Reply
share
Share

STBT: SELL CIPLA BELOW 479.50
Like
reply
Reply
share
Share

Buy cipla cash
479.5-476.5
Sl 473.5
Tgt 486/491+
Like
reply
Reply (1)
share
Share
Latest replies
DREAM BIG VIEW @dreambig
Nov 22 7:05 PM

Cipla buy updates
478.9 to 482.3
3+ points dn
🎉💰 🎉💰🎉💰
Book as comforts

INTRADAY SHORT CIPLA AT 478, TARGET 474, 470, SL 482
1
reply
Reply
share
Share
Shardia in CIPLA
475 SL on cost now

473 safe start booking
Like
reply
Reply
share
Share
Shardia in CIPLA
Sell cipla 480 sl 486

475 SL on cost now
Like
reply
Reply
share
Share

Sell cipla 480 sl 486
Like
reply
Reply
share
Share
THE King of Equity in CIPLA
Cipla. Cmp @ 474 spot Worth buy from here and o...

Cipla
See the Rocking move
474 to 492.
In Such Range Bound market see our Stock specific Technical RESEARCH
18 Points Gain × 1000 lot size
= 18000++ Huge Profits
4%++ Huge Returns
For more technical levels ping me
Like
reply
Reply
share
Share

BUY CIPLA ABOVE 487.50 TGT 493.50/497.80 SL BELOW 483
1
reply
Reply (1)
share
Share
Latest replies
MCXTrades Rohit @mcxtrades
Nov 21 5:57 PM

489>>>

CIPLA 💉💉FUTU FIRST TARGET 🎯🎯DONE BOOK AGAIN HUGE PROFIT #cipla
Like
reply
Reply
share
Share
#Hansraj pandey in CIPLA
BUY CIPLA NOV FUTURE ABOVE 486 STOP LOSS 47...

CIPLA 💉💉FUTU FIRST TARGET 🎯🎯DONE BOOK AGAIN HUGE PROFIT
Like
reply
Reply
share
Share
ElliottWave Master in CIPLA
Target achieved

Next cipla target 495 and 500
Like
reply
Reply
share
Share
ElliottWave Master in CIPLA
Add positions for the targets of 490

Target achieved
Like
reply
Reply
share
Share

BUY CIPLA NOV FUTURE ABOVE 486 STOP LOSS 478.50 TARGET 490 / 498. #cipla
Like
reply
Reply
share
Share

BUY CIPLA NOV FUTURE ABOVE 486 STOP LOSS 478.50 TARGET 490 / 498.
Like
reply
Reply
share
Share
INTRADAY TADKA
FUTURE LOVER #CIPLA FUT BUY ABOVE 481 TGT OPEN

#CIPLA FUT MADE HIGH 484
(3000 PROFIT)
Like
reply
Reply
share
Share

CIPLA - chart - 446914
Head and Shoulders Bottom Spotted In Cipla
Target Rang: 500-530.
1
reply
Reply (1)
share
Share
Latest replies
ElliottWave Master @ygtrader
Nov 20 7:20 PM

*range
ElliottWave Master in CIPLA
Target achieved

Add positions for the targets of 490
Like
reply
Reply
share
Share

BUY CIPLA CMP 483-484 SL 467 TGT 495-510-520
Like
reply
Reply (1)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 21 7:27 PM

491+ enjoy

FUTURE LOVER
#CIPLA FUT BUY ABOVE 481 TGT OPEN
Like
reply
Reply
share
Share
ElliottWave Master in CIPLA
Targets if 480 achieved, Can book partial profi...

Target achieved
Like
reply
Reply
share
Share
ElliottWave Master in CIPLA
Cipla buying recommend Cipla headed For 480 lev...

Targets if 480 achieved,
Can book partial profit,
Next target follows:
485-490
Like
reply
Reply
share
Share

Cipla.
Cmp @ 474 spot
Worth buy from here and on every dip for short term tgt 481-489++
Reminder @
Will see sharp upmove above 490 sustain/close.
SL @ your own risk or ping me for technical levels
Like
reply
Reply
share
Share

Buy cipla 480 ce @8.20 tgt 10 sl 7.95
9🔥🔥
Like
reply
Reply
share
Share

Cipla buying recommend
Cipla headed For 480 levels, if it closes above 480 then it can even reach 500 if strong upward momentum persists.
Like
reply
Reply
share
Share
Shardia in CIPLA
Buy cipla 464.5 sl 459

avoid fired
Like
reply
Reply
share
Share

Buy cipla 464.5 sl 459
Like
reply
Reply
share
Share

CIPLA - chart - 443670

Like
reply
Reply
share
Share
DREAM BIG VIEW in CIPLA
Sell cipla cash. 464-468 Sl 472 Tgt 458/452

Cipla sell updates.
464.5 to 457.7
Tgt 1 dn 458
6+ pointa gain
🎉💰 💰 💰
Like
reply
Reply
share
Share

Sell cipla cash.
464-468
Sl 472
Tgt 458/452
Like
reply
Reply (1)
share
Share
Latest replies
DREAM BIG VIEW @dreambig
Nov 18 7:19 PM

464.5 to 462.1

Look bearish weekly basis
Like
reply
Reply
share
Share
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA Share Price - Technicals

    keyboard_arrow_down
    CIPLA - 52 Week High₹586
    CIPLA - 52 Week Low₹389.55
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    7-Nov-19SharekhanBuy540
    6-Nov-19Prabhudas LilladherReduce439
    3-Oct-19EdelweissBuy500
    13-Aug-19SharekhanBuy650
    9-Aug-19ICICIdirect.comHold520
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 9457.4457.75444.6447.9
    Dec 6463467454455.45
    Dec 5469.5470.3460.4461.6
    Dec 4463471.85462470
    Dec 3465465.85460464.25
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹466.27
    30 Day Moving Average₹466.19
    50 Day Moving Average₹454
    100 Day Moving Average₹476.12
    200 Day Moving Average₹512.44
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 19 1:38 AM
    How Cipla's Umang Vohra is trying to invigorate the 84 year old company
    Moneycontrol
    NewsBot
    Oct 18 6:53 PM
    Cipla shares gain after acquiring anti-infective drug Elores
    Moneycontrol
    NewsBot
    Oct 18 1:38 PM
    Stocks in the news: Reliance Industries, Ambuja Cements, Aurobindo Pharma, KPR Mill
    Moneycontrol
    NewsBot
    Oct 17 3:28 AM
    How Wellthy Therapeutics is redefining healthcare delivery with a digital pill
    Moneycontrol
    NewsBot
    Oct 14 9:18 PM
    Cipla Q2 PAT seen up 17% YoY to Rs. 442.8 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 12 5:08 PM
    Stock movers for the week: Bharti Airtel, Century Textiles, Bandhan Bank top the charts
    Moneycontrol
    NewsBot
    Oct 11 8:23 PM
    Cipla rebounds 4% as management alleviates concerns on Goa unit observations
    Moneycontrol
    NewsBot
    Oct 10 4:48 PM
    Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return
    Moneycontrol
    NewsBot
    Oct 10 1:38 AM
    Indian pharma market sees growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 9 11:08 PM
    Indian pharma market registers growth of 11.5% in Q2FY20
    Moneycontrol
  • CIPLA - Related Communities

    keyboard_arrow_down
    MCX:RBDPMOLEIN
    MCX:PEPPER
    MCX:CASTORSEED
    MCX:CARDAMOM
    MCX:BRASSPHY
    Affle (India) Limited
    MCX:COTTON
    SPICEJET LTD Sector: Transport
    IRCTC Sector: Miscellaneous
    Share and discuss algorithms, strateg...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.